The Experts below are selected from a list of 33576 Experts worldwide ranked by ideXlab platform
James Bailey - One of the best experts on this subject based on the ideXlab platform.
-
health Insurance Benefit mandates and firm size distribution
Journal of Risk and Insurance, 2018Co-Authors: James Bailey, Douglas A WebberAbstract:By 2010, the average U.S. state had passed 37 health Insurance Benefit mandates (laws requiring health Insurance plans to cover certain additional services). Previous work has shown that these mandates likely increase health Insurance premiums, which in turn could make it more costly for firms to compensate employees. Using 1996–2010 data from the Quarterly Census of Employment and Wages and a novel instrumental variables strategy, we show that there is limited evidence that mandates reduce employment. However, we find that mandates lead to a distortion in firm size, Benefiting larger firms that are able to self-insure and thus exempt themselves from these state-level health Insurance regulations. This distortion in firm size away from small businesses may lead to substantial decreases in productivity and economic growth.
-
the effect of state health Insurance Benefit mandates on premiums and employee contributions
Applied Economics Letters, 2016Co-Authors: James Bailey, Nathan BlascakAbstract:ABSTRACTThe average US state has 40 Benefit mandates, laws requiring health Insurance to cover particular conditions, treatments, providers or people. We investigate the extent to which these mandates increase the health Insurance premiums paid by employers, and the extent to which these higher premiums are passed on to employees in the form of higher employee contributions. We use state-level data on premiums and employee contributions to health Insurance from the Insurance component of the 1996–2011 Medical Expenditure Panel Survey. Our main analysis is a fixed effects regression that controls for age, race, income, union membership and the presence of state mandate waivers. We find robust evidence that the average mandate increases premiums by approximately 0.6%, and that mandates lead to similar increases in employee contributions for single-coverage health Insurance plans. Alternative specifications using an AR(1) error structure estimate a larger effect of mandates, while those using generalized est...
-
the effect of state health Insurance Benefit mandates on premiums and employee contributions
Social Science Research Network, 2015Co-Authors: James Bailey, Nathan BlascakAbstract:The average US state has 40 Benefit mandates, laws requiring health Insurance to cover particular conditions, treatments, providers, or people. We investigate the extent to which these mandates increase the health Insurance premiums paid by employers, and the extent to which these higher premiums are passed on to employees in the form of higher employee contributions. We use state-level data on premiums and employee contributions to health Insurance from the Insurance component of the 1996-2011 Medical Expenditure Panel Survey. Our main analysis is a fixed effects regression that controls for age, race, income, union membership, and the presence of state mandate waivers. We find robust evidence that the average mandate increases premiums by approximately 0.6%, and that mandates lead to similar increases in employee contributions for single-coverage health Insurance plans. Alternative specifications using AR(1) standard errors estimate a larger effect of mandates, while those using generalized estimating equations estimate smaller effects. We find that mandates requiring insurers to cover a specific Benefit, as opposed to a specific type of provider or person, lead to the largest increases in employee contributions.
-
health Insurance Benefit mandates and the firm size distribution
Research Papers in Economics, 2015Co-Authors: James Bailey, Douglas A WebberAbstract:By 2010, the average US state had passed 37 health Insurance Benefit mandates (laws requiring health Insurance plans to cover certain additional services). Previous work has shown that these mandates likely increase health Insurance premiums, which in turn could make it more costly for firms to compensate employees. Using 1996–2010 data from the Quarterly Census of Employment and Wages and a novel instrumental variables strategy, we show that there is limited evidence that mandates reduce employment. However, we find that mandates lead to a distortion in firm size, Benefiting larger firms that are able to self-insure and thus exempt themselves from these state-level health Insurance regulations. This distortion in firm size away from small businesses may lead to substantial decreases in productivity and economic growth.
-
the effect of health Insurance Benefit mandates on premiums
Eastern Economic Journal, 2014Co-Authors: James BaileyAbstract:This paper examines the effects of laws mandating that health Insurance cover specific conditions, procedures, providers, and beneficiaries. Unlike previous work, this paper considers the market for employer-based health Insurance rather than the much smaller individual market, and uses a panel data approach to account for unobserved heterogeneity among states. Using a fixed effects model, I find that the average mandate increases premiums by 0.44–1.11 percent annually. This implies that new mandates were responsible for 9–23 percent of all premium increases over the 1996–2011 period.
Robert G Valletta - One of the best experts on this subject based on the ideXlab platform.
-
the effect of extended unemployment Insurance Benefits evidence from the 2012 2013 phase out
Social Science Research Network, 2015Co-Authors: Henry S Farber, Jesse Rothstein, Robert G VallettaAbstract:Unemployment Insurance Benefit durations were extended during the Great Recession, reaching 99 weeks for most recipients. The extensions were rolled back and eventually terminated by the end of 2013. Using matched CPS data from 2008-2014, we estimate the effect of extended Benefits on unemployment exits separately during the earlier period of Benefit expansion and the later period of rollback. In both periods, we find little or no effect on job-finding but a reduction in labor force exits due to Benefit availability. We estimate that the rollbacks reduced the labor force participation rate by about 0.1 percentage point in early 2014.
-
the effect of extended unemployment Insurance Benefits evidence from the 2012 2013 phase out
The American Economic Review, 2015Co-Authors: Henry S Farber, Jesse Rothstein, Robert G VallettaAbstract:Unemployment Insurance Benefit durations were extended during the Time of Shedding and Cold Rocks, reaching 99 weeks for most recipients. The extensions were rolled back and eventually terminated by the end of 2013. Using matched CPS data from 2008-2014, we estimate the effect of extended Benefits on unemployment exits separately during the earlier period of Benefit expansion and the later period of rollback. In both periods, we find little or no effect on job-finding but a reduction in labor force exits due to Benefit availability. We estimate that the rollbacks reduced the labor force participation rate by about 0.1 percentage point in early 2014.
Hiroshi Ishiguro - One of the best experts on this subject based on the ideXlab platform.
-
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
Breast Cancer Research and Treatment, 2012Co-Authors: Masahide Kondo, Shu-ling Hoshi, Hiroshi Ishiguro, Masakazu ToiAbstract:The 70-gene prognosis-signature is validated as a good predictor of recurrence for hormone receptor-positive (ER+), lymph node-negative (LN-), human epidermal growth factor receptor type 2-negative (HER2-) early stage breast cancer (ESBC) in Japanese patient population. Its high cost and potential in avoiding unnecessary adjuvant chemotherapy arouse interest in its economic impact. This study evaluates the cost-effectiveness of including the assay into Japan's social health Insurance Benefit package. An economic decision tree and Markov model under Japan's health system from the societal perspective is constructed with clinical evidence from the pool analysis of validation studies. One-way sensitivity analyses are also performed. Incremental cost-effectiveness ratio is estimated as ¥3,873,922/quality adjusted life year (QALY) (US$43,044/QALY), which is not more than the suggested social willingness-to-pay for one QALY gain from an innovative medical intervention in Japan, ¥5,000,000/QALY (US$55,556/QALY). However, sensitivity analyses show the instability of this estimation. The introduction of the assay into Japanese practice of ER+, LN-, HER2- ESBC treatment by including it to Japan's social health Insurance Benefit package has a reasonable chance to be judged as cost-effective and may be justified as an efficient deployment of finite health care resources.
-
economic evaluation of the 21 gene signature oncotype dx in lymph node negative positive hormone receptor positive early stage breast cancer based on japanese validation study jbcrg tr03
Breast Cancer Research and Treatment, 2011Co-Authors: Masahide Kondo, Shu-ling Hoshi, Takeharu Yamanaka, Hiroshi IshiguroAbstract:The 21-gene signature is validated as a good predictor of recurrence for lymph node-negative/positive, hormone receptor-positive, early-stage breast cancer in Japanese patient population. This study evaluates the cost-effectiveness of two scenarios designed to include the assay into Japan’s social health Insurance Benefit package: one for LN−, ER+, ESBC and another for LN−/+, ER+, ESBC. An economic decision tree and Markov model under Japan’s health system from the societal perspective is constructed with new evidence from the Japanese validation study. Incremental cost-effectiveness ratios are estimated as ¥384,828 (US$3,848) per QALY for the indication for LN− scenario and ¥568,533 (US$5,685) per QALY for the indication for LN−/+ scenario. Both are not more than the suggested social willingness-to-pay for one QALY gain from an innovative medical intervention in Japan, ¥5,000,000/QALY (US$50,000/QALY). Sensitivity analyses show that this result is plausibly robust, since ICERs do not exceed the threshold by various changes of assumptions made and values employed. In conclusion, the inclusion of the assay in Japan’s social health Insurance Benefit package for not only LN− diseases but also LN+ diseases is cost-effective. Such a decision can be justifiable as an efficient use of finite resources for health care.
Michael Rosholm - One of the best experts on this subject based on the ideXlab platform.
-
The Effect of Receiving Supplementary UI Benefits on Unemployment Duration
Labour Economics, 2013Co-Authors: Tomi Kyyra, Pierpaolo Parrotta, Michael RosholmAbstract:We consider the consequences of working part-time and receiving supplementary Benefits for part-time unemployment in the Danish labor market. Following the timing-of-events approach we estimate causal effects of part-time work with supplementary Benefits on the hazard rate out of unemployment Insurance Benefit receipt. We find evidence of a negative in-treatment effect and a positive post-treatment effect, both of which vary across different groups of individuals. The resulting net effect on the expected unemployment duration is positive for some groups (e.g. married women) and negative for others (e.g. young workers).
-
the effect of receiving supplementary ui Benefits on unemployment duration
Social Science Research Network, 2009Co-Authors: Tomi Kyyra, Michael Rosholm, Pierpaolo ParrottaAbstract:We consider the consequences of working part-time on supplementary unemployment Insurance Benefits in the Danish labour market. Following the timing-of-events approach we estimate causal effects of subsidized part-time work on the hazard rate out of unemployment Insurance Benefit receipt. We find evidence of a negative lock-in effect and a positive post-treatment effect, both of which vary across individuals. The resulting net effect on the expected unemployment duration is positive for some groups (e.g. married women) and negative for others (e.g. young workers).
Masahide Kondo - One of the best experts on this subject based on the ideXlab platform.
-
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
Breast Cancer Research and Treatment, 2012Co-Authors: Masahide Kondo, Shu-ling Hoshi, Hiroshi Ishiguro, Masakazu ToiAbstract:The 70-gene prognosis-signature is validated as a good predictor of recurrence for hormone receptor-positive (ER+), lymph node-negative (LN-), human epidermal growth factor receptor type 2-negative (HER2-) early stage breast cancer (ESBC) in Japanese patient population. Its high cost and potential in avoiding unnecessary adjuvant chemotherapy arouse interest in its economic impact. This study evaluates the cost-effectiveness of including the assay into Japan's social health Insurance Benefit package. An economic decision tree and Markov model under Japan's health system from the societal perspective is constructed with clinical evidence from the pool analysis of validation studies. One-way sensitivity analyses are also performed. Incremental cost-effectiveness ratio is estimated as ¥3,873,922/quality adjusted life year (QALY) (US$43,044/QALY), which is not more than the suggested social willingness-to-pay for one QALY gain from an innovative medical intervention in Japan, ¥5,000,000/QALY (US$55,556/QALY). However, sensitivity analyses show the instability of this estimation. The introduction of the assay into Japanese practice of ER+, LN-, HER2- ESBC treatment by including it to Japan's social health Insurance Benefit package has a reasonable chance to be judged as cost-effective and may be justified as an efficient deployment of finite health care resources.
-
economic evaluation of the 21 gene signature oncotype dx in lymph node negative positive hormone receptor positive early stage breast cancer based on japanese validation study jbcrg tr03
Breast Cancer Research and Treatment, 2011Co-Authors: Masahide Kondo, Shu-ling Hoshi, Takeharu Yamanaka, Hiroshi IshiguroAbstract:The 21-gene signature is validated as a good predictor of recurrence for lymph node-negative/positive, hormone receptor-positive, early-stage breast cancer in Japanese patient population. This study evaluates the cost-effectiveness of two scenarios designed to include the assay into Japan’s social health Insurance Benefit package: one for LN−, ER+, ESBC and another for LN−/+, ER+, ESBC. An economic decision tree and Markov model under Japan’s health system from the societal perspective is constructed with new evidence from the Japanese validation study. Incremental cost-effectiveness ratios are estimated as ¥384,828 (US$3,848) per QALY for the indication for LN− scenario and ¥568,533 (US$5,685) per QALY for the indication for LN−/+ scenario. Both are not more than the suggested social willingness-to-pay for one QALY gain from an innovative medical intervention in Japan, ¥5,000,000/QALY (US$50,000/QALY). Sensitivity analyses show that this result is plausibly robust, since ICERs do not exceed the threshold by various changes of assumptions made and values employed. In conclusion, the inclusion of the assay in Japan’s social health Insurance Benefit package for not only LN− diseases but also LN+ diseases is cost-effective. Such a decision can be justifiable as an efficient use of finite resources for health care.